The Functional Consequences of Polymorphisms in the Human PON1 Gene

[1]  A. Hoffman,et al.  Epigenetics of Long-Range Chromatin Interactions , 2007, Pediatric Research.

[2]  P. Peeters,et al.  Genetic and environmental determinants of the PON‐1 phenotype , 2007, European journal of clinical investigation.

[3]  J. Blangero,et al.  Sex‐specific QTL effects on variation in paraoxonase 1 (PON1) activity in Mexican Americans , 2007, Genetic epidemiology.

[4]  S. Krieger,et al.  Sp1/Sp3 and DNA-methylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells , 2007, BMC Molecular Biology.

[5]  J. Blangero,et al.  Multiple QTLs Influence Variation in Paraoxonase 1 Activity in Mexican Americans , 2006, Human biology.

[6]  E. Hodgson,et al.  Inhibition of the Human Liver Microsomal and Human Cytochrome P450 1A2 and 3A4 Metabolism of Estradiol by Deployment-Related and Other Chemicals , 2006, Drug Metabolism and Disposition.

[7]  N. Holland,et al.  PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity , 2006, Pharmacogenetics and genomics.

[8]  L. Costa,et al.  Modulation of paraoxonase (PON1) activity. , 2005, Biochemical pharmacology.

[9]  S. Deakin,et al.  Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. , 2004, Clinical science.

[10]  Tom R. Gaunt,et al.  The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis , 2004, BMC Genetics.

[11]  Dan S. Tawfik,et al.  Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes , 2004, Nature Structural &Molecular Biology.

[12]  J. Danesh,et al.  Four paraoxonase gene polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies , 2004, The Lancet.

[13]  De-Pei Liu,et al.  Paraoxonase gene polymorphisms, oxidative stress, and diseases , 2003, Journal of Molecular Medicine.

[14]  B. L. Du,et al.  Future Studies of Low-Activity PON1 Phenotype Subjects May Reveal How PON1 Protects Against Cardiovascular Disease , 2003 .

[15]  R. Pannbacker.  Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects , 2003 .

[16]  S. Deakin,et al.  Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. , 2003, The Biochemical journal.

[17]  C. Carlson,et al.  Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. , 2003, Pharmacogenetics.

[18]  E. Hodgson,et al.  Inhibition and activation of the human liver microsomal and human cytochrome P450 3A4 metabolism of testosterone by deployment-related chemicals. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[19]  P. Durrington,et al.  PON1 in Other Diseases , 2002 .

[20]  M. Jokanović.  Biotransformation of organophosphorus compounds. , 2001, Toxicology.

[21]  P. Durrington,et al.  Paraoxonase Status in Coronary Heart Disease: Are Activity and Concentration More Important Than Genotype? , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[22]  G. Jarvik,et al.  Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. , 2001, American journal of human genetics.

[23]  S. Deakin,et al.  Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. , 2001, Journal of lipid research.

[24]  G. Jarvik,et al.  Polymorphisms in the human paraoxonase (PON1) promoter. , 2001, Pharmacogenetics.

[25]  A. Tward,et al.  Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. , 2000, Pharmacogenetics.

[26]  Y. Ikeda,et al.  A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. , 2000, Atherosclerosis.

[27]  I. Leviev,et al.  Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[28]  D. Shih,et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.

[29]  R. James,et al.  Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[30]  R. Fenske,et al.  Simulated dermal contamination with capillary samples and field cholinesterase biomonitoring. , 1997, Journal of toxicology and environmental health.

[31]  P. Froguel,et al.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. , 1997, The Journal of clinical investigation.

[32]  M. Keifer,et al.  The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin , 1996, Nature Genetics.

[33]  P. Elwood,et al.  Structural and functional analysis of the human KB cell folate receptor gene P4 promoter: cooperation of three clustered Sp1-binding sites with initiator region for basal promoter activity. , 1995, Biochemistry.

[34]  J. Chambers,et al.  Organophosphate detoxication potential of various rat tissues via A-esterase and aliesterase activities. , 1995, Toxicology letters.

[35]  M. Abou‐Donia,et al.  In vitro effect of chlorpyrifos oxon on muscarinic receptors and adenylate cyclase. , 1995, Neurotoxicology.

[36]  T. Ma,et al.  Role of detoxication pathways in acute toxicity levels of phosphorothionate insecticides in the rat. , 1994, Life sciences.

[37]  S. Adkins,et al.  Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. , 1993, American journal of human genetics.

[38]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.

[39]  R. Humbert,et al.  Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. , 1991, Biochemistry.

[40]  P. Durrington,et al.  Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein , 1991, FEBS letters.

[41]  R. Zech,et al.  Organophosphate splitting serum enzymes in different mammals. , 1974, Comparative biochemistry and physiology. B, Comparative biochemistry.